• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-1MEF filed by Aytu BioPharma Inc.

    6/6/25 6:01:54 AM ET
    $AYTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AYTU alert in real time by email
    S-1MEF 1 aytu20250605_s1mef.htm FORM S-1MEF aytu20250605_s1mef.htm

     

     

    As filed with the U.S. Securities and Exchange Commission on June 5, 2025

     

    Registration No. 333-        

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-1
    REGISTRATION STATEMENT
    UNDER THE
    SECURITIES ACT OF 1933

    logo01.jpg

     

    AYTU BIOPHARMA, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware
    (State or other jurisdiction of
    incorporation or organization)

    2834
    (Primary Standard Industrial
    Classification Code Number)

    47-0883144
    (I.R.S. Employer
    Identification Number)

     

    7900 East Union Avenue, Suite 920
    Denver, Colorado 80237
    (720) 437-6580
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Joshua R. Disbrow
    Chief Executive Officer

    Aytu BioPharma, Inc.
    7900 East Union Avenue, Suite 920
    Denver, Colorado 80237
    Telephone: (720) 437-6580
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Anthony W. Epps
    Joshua B. Erekson
    Dorsey & Whitney LLP
    1400 Wewatta Street, Suite 400
    Denver, Colorado 80202
    (303) 352-1109

    David Danovitch

    Aaron Schleicher

    Sullivan & Worcester LLP

    1251 Avenue of the Americas

    New York, New York 10019

    (212) 660-3060

     

     

     

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-287728)

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

       

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.

     

     

     

     

    EXPLANATORY NOTE

     

    This 462(b) Registration Statement relates to the public offering of securities (the “Offering”) contemplated by the Registration Statement on Form S-1, as amended, (File No. 333-287728) which was initially filed with the United States Securities and Exchange Commission (the “SEC”) on June 2, 2025, and which was declared effective by the SEC on June 5, 2025 (the “Prior Registration Statement”).

     

    This Registration Statement on Form S-1 is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the purposes of registering additional securities of the same class as were included in the Prior Registration Statement, representing an increase in the maximum aggregate offering price by $2,760,000, which includes $2,400,000 worth of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and/or an additional $2,400,000 worth of prefunded warrants to purchase $2,400,000 worth of shares of Common Stock to be issued to the underwriters and an additional $360,000 worth of shares of Common Stock to be issued to the underwriters as an underwriters’ option.

     

    The additional securities that are being registered for sale are in an amount and at a price that together represents no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 to the Prior Registration Statement.

     

    The contents of the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference.

     

    The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Exhibit Description 

    5.1

     

    Opinion of Dorsey & Whitney LLP.

    23.1

     

    Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm. 

    23.2

     

    Consent of Dorsey & Whitney LLP (included in Exhibit 5.1). 

    24.1*

     

    Power of Attorney. 

    107

     

    Filing Fee Table.

                   
                         

    *

    Previously filed on the signature page to the Prior Registration Statement and incorporated by reference herein.

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado, on June 5, 2025.

     

     

    AYTU BIOPHARMA, INC. 

         
     

    By:

    /s/ Joshua R. Disbrow

     

    Name: Joshua R. Disbrow

     

    Title: Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature

     

    Title

     

    Date

             

    /s/ Joshua R. Disbrow

         

    June 5, 2025

    Joshua R. Disbrow

     

    Chief Executive Officer and Director (Principal Executive Officer)

       
             
    *      

    June 5, 2025

    Ryan J. Selhorn

     

    Chief Financial Officer (Principal Financial and Accounting Officer)

       
             

    *

         

    June 5, 2025

    John A. Donofrio, Jr.

     

    Chairman

       
             

    *

         

    June 5, 2025

    Carl C. Dockery

     

    Director

       
             

    *

         

    June 5, 2025

    Abhinav Jain

     

    Director

       
             

    *

         

    June 5, 2025

    Vivian Liu

     

    Director

       

     

    * /s/ Joshua R. Disbrow Attorney-in-Fact

     

     

     
    Get the next $AYTU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYTU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AYTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Pyszczymuka Greg converted options into 209 shares, increasing direct ownership by 0.89% to 23,602 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/31/25 4:34:24 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Selhorn Ryan J converted options into 105 shares, increasing direct ownership by 0.66% to 16,000 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 7:22:47 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 1:35:04 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    SEC Filings

    See more
    • Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)

      6/6/25 4:07:43 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)

      6/6/25 4:07:02 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1MEF filed by Aytu BioPharma Inc.

      S-1MEF - AYTU BIOPHARMA, INC (0001385818) (Filer)

      6/6/25 6:01:54 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

      DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.The fireside chat will take place at 10:00 a.m. Eastern Time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/aytu. A replay of the fireside chat will also be available through same links.1

      1/6/25 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Disclosure Notification

      DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL., NO. 2022-0807-MTZ (THE "ACTION").TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. ("AYTU" OR THE "COMPANY") (NASDAQ:AYTU) AS OF OCTOBER 9, 2024 (THE "RECORD DATE") ("CURRENT AYTU SHAREHOLDERS").YOU ARE HEREBY NOTIFIED that the Settling Parties to the Action have reached a settlement ("Settlement") to resolve the issues raised in the Action against Defendants

      12/3/24 11:45:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

      DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year."We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "During fiscal 2024, we continued to successfully reposition

      11/22/24 9:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aytu BioPharma Inc.

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      11/13/24 5:36:50 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aytu BioPharma Inc.

      SC 13D/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      6/18/24 4:30:29 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aytu BioPharma Inc. (Amendment)

      SC 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)

      2/13/24 4:25:46 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Aytu BioPharma with a new price target

      Cantor Fitzgerald initiated coverage of Aytu BioPharma with a rating of Overweight and set a new price target of $11.00

      3/30/21 6:27:35 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Disbrow Joshua R. bought $19,500 worth of shares (15,000 units at $1.30), increasing direct ownership by 21% to 86,591 units (SEC Form 4)

      4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)

      3/3/25 1:35:04 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Leadership Updates

    Live Leadership Updates

    See more
    • Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

      Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to [email protected]'s presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.If attendees are not able to

      11/30/23 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Appoints Mark Oki as Chief Financial Officer

      ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki will serve as a member of Aytu's executive committee and will report to Josh Disbrow, chief executive officer. Mr. Oki will provide leadership and oversight of the company's financial operations and planning, accounting, information technology and select other functions."On behalf of the entire company, I am delighted to welcome Mark to Aytu and look forward to partnering with him as we

      1/4/22 8:00:00 AM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

      - Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company -- Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development pipeline -- Record quarter for consumer health division with revenue reaching $8.4 million and Rx division revenue up 9% over same quarter last year -- Grew leadership team with three executives including CFO, Rich Eisenstadt - - Management to host live conference call and webcast today at 4:30 p.m. ET -ENGLEWOOD, CO / ACCESSWIRE / May 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commerciali

      5/17/21 4:01:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AYTU
    Financials

    Live finance-specific insights

    See more
    • Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

      Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flowRyan Selhorn promoted to Chief Financial OfficerCompany to host conference call and webcast today, November 13, 2024, at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ann

      11/13/24 4:05:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

      DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its first quarter of fiscal 2025, after the market close on Wednesday, November 13, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 13, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, November 13, 2024, at 4:30 p.m. Eastern timeCall-in Information: Interested parties can access the conference call by dialing (877) 545-

      11/6/24 5:20:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

      Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023$20.0 million cash balance at June 30, 2024Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levelsCompany to host conference call and webcast today, September 26, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESSWIRE / September 26, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel ther

      9/26/24 4:15:00 PM ET
      $AYTU
      Biotechnology: Pharmaceutical Preparations
      Health Care